Atrial natriuretic peptide plasma concentration (ANP) and pulmonary hemodynamics (HEMO) after acute nitric oxide inhalation (NO) in patients with connective tissue disease and pulmonary artery hypertension (CTDPH)

C. Marini, B. Formichi, M. Emdin (Pisa, Italy)

Source: Annual Congress 2005 - Pulmonary hypertension

Session: Pulmonary hypertension
Session type: Thematic Poster Session
Number: 3615

Disease area: Pulmonary vascular diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Marini, B. Formichi, M. Emdin (Pisa, Italy). Atrial natriuretic peptide plasma concentration (ANP) and pulmonary hemodynamics (HEMO) after acute nitric oxide inhalation (NO) in patients with connective tissue disease and pulmonary artery hypertension (CTDPH). Eur Respir J 2005; 26: Suppl. 49, 3615

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders Source: Eur Respir J 2002; 19: 664-671 Year: 2002
Reduced pulmonary capillary volume (Vc) is responsable for the increased alveolar exhaled nitric oxide (C_ANO) in patients with progressive systemic sclerosis (PSS) and pulmonary hypertension (PH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005
N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2005; 25: 509-513 Year: 2005
Can brain natriuretic peptide (BNP) be a predictor for pulmonary arterial hypertension? Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007
Expression of endothelial nitric oxide synthase (eNOS) and endothelin-1 (ET-1) in pulmonary arteries of patients with severe COPD Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation Year: 2003
Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012
Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Epoprostenol (EPT) for acute reactivity testing (AVT) in pulmonary artery hypertension (PAH) Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes Source: Eur Respir J 2002; 20: 52-58 Year: 2002
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Biomarkers in pulmonary hypertension Source: Eur Respir J 2008; 32: 503-512 Year: 2008
Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Eur Respir J 2008; 32: 1289-1294 Year: 2008
Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017
Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH) Source: Eur Respir J 2003; 22: Suppl. 45, 270s Year: 2003
Pulmonary artery pressure (PAP) reduction by systemic and inhaled S-nitroso-N-acetyl-penicillamine (SNAP) in an isolated rabbit lung model of acute lung injury Source: Eur Respir J 2002; 20: Suppl. 38, 37s Year: 2002
Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH) Source: Eur Respir J 2001; 18: Suppl. 33, 83s Year: 2001
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 881-891 Year: 2008